Pfizer (NYSE:PFE) trades at $25.62, pays a 6.7% dividend yield, and just posted five straight quarterly EPS beats before ...

Pfizer stock may not be cheap enough to buy yet, but it's certainly too cheap to sell.

Investors are clearly worried about the safety of Pfizer's dividend, which is reasonable.

One company posts rapid revenue growth but remains unprofitable, while the other boasts global scale and steady cash flow.

Pfizer (NYSE:PFE | PFE Price Prediction) is in the middle of its biggest reinvention in a generation, leaning on the Seagen ...

Many income investors probably have mixed emotions about stocks with ultra-high dividend yields. On one hand, they love the tremendous income these stocks provide. On the other hand, they might worry ...

Pfizer announced on Sept. 30 it will participate in a new government direct-to-consumer drug sale website. TrumpRx, which is expected to launch at the beginning of next year, will allow patients to ...

Pfizer could attract investors if Warsh's "regime change" at the Fed leads to market turbulence.

Pfizer showcased multiple late-breakers at the American Society of Clinical Oncology’s annual conference but its biggest data ...